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Abstract  
Crohn’s disease (CD) is characterized as a chronic immune-mediated inflammatory 
disorder of the gastrointestinal tract. Current consensus surrounding the cause of the 
disease suggests a complex interplay between genetic susceptibility, the intestinal 
microbiome and environmental factors, leading to the aberrant Th1 and Th17 cell 
driven autoimmune response.  
 
Vitamin D deficiency is common in CD patients, and longstanding deficiency has 
been associated with reduced bone mineral density (BMD). Accumulating evidence 
now suggests that in addition to maintaining skeletal integrity, vitamin D also plays 
an integral role in regulating the general immune response, a function employed via 
its genomic actions on the vitamin D receptor (VDR). The VDR is expressed in all 
immune cells and both directly and indirectly targeted by the bioactive form of 
vitamin D, 1,25-Dihydroxyvitamin D (1,25[OH]₂D). Impaired regulation or deficiency 
of the vitamin has been linked to the promotion of self-reactive T cell development, 
loss of immune tolerance to self-structures and experimental colitis in animal 
models, whilst the subsequent administration of the vitamin in these models resulted 
in the improvement of immune-mediated symptoms. In addition, low vitamin D has 
been associated with disease activity in CD patients, and supplementation appears to 
be beneficial in improving clinical scores and reducing inflammation. Therefore, the 
primary aims of this paper were to review the molecular evidence supporting the 
immunoregulatory roles of vitamin D and its supplementation in the CD patient, 
based upon existing literature. The physiological processes, accepted serum 
concentration values and its well-recognized role in bone health were also 
summarized.  
 
Introduction 
Crohn’s disease (CD), a subtype of inflammatory bowel disease (IBD), (Ulcerative 
colitis (UC), being the second subtype), is characterized as a chronic immune-
mediated inflammatory disorder involving the host self-tissue damage of the 
gastrointestinal tract.¹¯⁴ Although the exact pathogenesis of CD is unknown, it is 
believed to result from a dysregulated Th1 and Th17 cell driven immune response 
triggered by the host intestinal microbiome, and a range of poorly defined 
environmental factors, in genetically susceptible individuals.³  
 
Vitamin D is derived from skin exposure to ultraviolet (UV) sunlight, and is well-
described for its function in the maintenance of calcium and phosphorus 
homeostasis and skeletal integrity.³¯⁶ Deficiency in the vitamin is commonly found 
in the CD patient due to the inherent nature of the disease, and longstanding 
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deficiency is associated with reduced bone mineral density (BMD) and osteomalacia 
in the adult CD patient.⁷¯¹¹   
 
In addition to bone health, accumulating evidence has revealed that vitamin D also 
plays an integral role in regulating the immune system, an action employed via its 
genomic effects on the vitamin D receptor (VDR).  The VDR is expressed in all 
immune cells, and is directly and indirectly targeted by the bioactive form of vitamin 
D, 1,25-dihydroxyvitamin D (1,25[OH] ₂D).¹²¯¹⁶  Both in vivo and in vitro, the 
active form of vitamin D has been shown to regulate the development and function of 
T-cells, anti-microbial peptides and dendritic cells (DCs), together with modulating 
the up-regulated Th1 cell response associated with immune-mediated disease 
pathogenesis.¹²¯¹⁷ In murine models, vitamin D deficiency or the impairment of its 
regulatory mechanisms, have been linked to the promotion of self-reactive T-cell and 
experimental IBD development.  In these same models, the administration of 
1,25(OH)₂D₃ resulted in an improvement of these immune-mediated 
symptoms.¹²¯¹⁷ The association between vitamin D and its modulatory effect on 
disease activity in the CD patient has also recently been demonstrated in cross-
sectional studies and small clinical trials, notwithstanding some discrepancies in the 
data.¹⁸ ¹⁹ With this background, it is not surprising that there has been a recent 
upsurge in the literature, providing a variety of preliminary data relating to the role 
of vitamin D in CD. Therefore this review will focus on highlighting the 
immunoregulatory role of vitamin D and the evidence supporting its 
supplementation in the context of the CD patient.  In addition the review will 
delineate the human synthesis, storage, and excretion of vitamin D, and the generally 
accepted serum concentration reference ranges as supported by the available 
evidence to date. 
 
Methods 
An extensive online search of the literature using the PUBMED 
(http://www.ncbi.nlm.nih.gov/pubmed) and EMBASE (http://www.embase.com/) 
databases was performed, which included the years 1966 through June 2013. Studies 
were restricted to the English language and found using the search terms “vitamin 
D”,  “25(OH)D”, “25(OH)2D3”, “25(OH)2D”, “vitamin D3”, “vitamin D2”, “Crohn’s 
disease”, “Inflammatory bowel disease”, “disease activity”, “autoimmune disease”, 
“autoimmunity”, “immunomodulation”, “supplementation”, “deficiency”, “animal 
models”, “measurement”, “cholecalciferol”, “ergocalciferol” in the full text option. 
The titles and abstracts of all studies were scanned to exclude any studies which were 
clearly not relevant to the topic. In addition, all references cited in original studies 
and in all reviews were identified. The aim was to review the immunoregulatory role 
of vitamin D in the context of the CD patient.  
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Vitamin D overview 
Synthesis 
Vitamin D is a “steroid-like” hormone, that exists in two forms; cholecalciferol 
(25[OH]D₃) also known as ‘vitamin D3’ (VD3), which is the naturally occurring form 
in humans, and ergocalciferol (25[OH]D₂) also known as ‘vitamin D2’ (VD2).²⁰ Food 
and supplements contain both forms of vitamin D (D2 and D3) however VD3 is rare 
in foods, and originates only from 7-dehydrocholesterol (7-DHC) in animal sources 
such as oily fish and egg yolk, while VD2 is mostly acquired from yeast and plant 
sterol sources (Table 1).¹⁴  ²⁰ ²¹ The primary source of pre-vitamin D3 is produced 
from UV irradiation of  7-DHC present in the skin, which rapidly undergoes 
isomerization to form vitamin D3, a process stimulated by body heat.⁵ ¹⁴                                                                                                               
The human ‘skin derived’ VD3 is the easiest and most cost-effective means of 
obtaining vitamin D, and adequate levels can be acquired from 5 to 30 minutes 
(depending on season) of sun exposure to the skin on the face, arms, back or legs 
twice every week, even on hazy or cloudy days.²² However, exposure may need to be 
increased by 5 to 16 times this amount in individuals with darker pigmented skin due 
to the higher melanin content reducing UV permeation to the skin (Table 1).²⁰ 
   
The dietary form of vitamin D is fat soluble in nature, which once digested, is 
required to undergo two sequential hydroxylations in the body to become biologically 
active (Figure1). Upon digestion, vitamin D is delivered via plasma to the liver by 
either chylomicron remnants, vitamin-D binding protein (DBP) or transcalciferon.²³ 
Vitamin D is then metabolized in the liver by the cytochrome P450 enzyme ‘25-
hydroxylase’ into ‘25-hydroxy vitamin D’ (25[OH]D), the major circulating and 
storage form of vitamin D in the body.²⁴ There are two ways in which 25(OH)D can 
be converted into its biologically (hormonally) active form calcitriol or ‘1,25-hydroxy 
vitamin D’ (1,25 [OH]₂D), one being in the proximal tubule of the kidneys.²⁵  ²⁶  
Renal conversion of the metabolite functions to regulate calcium metabolism, and is 
under tight control by the parathyroid hormone (PTH) and fibroblast growth factor 
(FGF23) in response to serum levels of calcium and phosphate, through the 
interaction between 1,25(OH)₂D with the VDR in the small intestine and on 
osteoblasts, and via the regulation of renal 25-hydroxyvitamin D-1-α-hydroxylase 
(1α-OHase) (CYP27B1), the latter acting as a rate limiting step in the pathway (Figure 
1).²⁰ ²⁷  The second conversion mechanism can take place within immune cells, such 
as T lymphocytes, B lymphocytes, macrophages and DCs. These cells possess 1α-
OHase and the VDR, enabling the localized activation of circulating 25(OH)D into 
1,25(OH)₂D or 1,25(OH)₂D₃, and the ability to respond in an autocrine or paracrine 
fashion to the metabolites.²⁸ Unlike renal 1α-OHase, cellular 1α-OHase is not up-
regulated by PTH, and thus immune cell production of 1,25(OH)₂D is dependent on 
serum 25(OH)D concentrations.²⁹  
 
Storage, circulation and excretion  
In the human body, 25(OH)D is the major storage and circulating form of vitamin D. 
Highest concentrations are found in the plasma, and usually measured in the serum, 
https://repository.uwc.ac.za/
4 
 
although adipose and muscle tissue are believed to store the largest pool of 
25(OH)D.³⁰ ³¹ The metabolites in the vitamin D pathway are circulated by DBP 
carrying 85-90%, and albumin, which carries the remaining 10-15%.³¹ In vivo, the 
circulating half-life of  25(OH)D  is approximately 2-3 weeks,³² however can last up 
to three months when considering adipose tissue store release.¹⁵ ³²  For excretion, 
25(OH)D, 1,25(OH)₂D and 1,25(OH)₂D₃  are converted into the inactive metabolites 
24,25(OH)₂D and 25(OH)D-26,23-lactone, by the enzyme 24-hydroxylase, allowing 
final elimination via urine and bile (Figure 1).³³ ³⁴  
 
Vitamin D Binding Protein (DBP)  
Vitamin D binding protein is the major circulatory protein for metabolites in the 
vitamin D pathway. The entry of the DBP-bound vitamin D metabolites (i.e., 
25[OH]D and 1,25[OH]₂D) into the cell can occur either through endocytosis (in 
which case DBP is also taken up),³⁵ or diffusion, though only small amounts of DBP-
bound vitamin D metabolites passively diffuse across cell membranes.¹⁵ ³⁶ Once the 
metabolite has entered the cell via endocytosis, DBP plays a role in regulating the 
intracellular actions of 25(OH)D and 1,25(OH)₂D, and thus their availability to the 
target organ.³⁷¯³⁹ In a small cohort of 49 adults, Powe et al³¹ demonstrated that 
DBP modulates the relationship between vitamin D and bone density, as a positive 
correlation was found between BMD and free bioavailable 25(OH)D, however not 
with total 25(OH)D. The authors also found that DBP concentrations and BMD were 
negatively correlated (r= -0.296).  Similarly, in the renal tubular cells, DBP also 
facilitates the cellular uptake of bound 25(OH)D enabling its presentation to renal 
1α-OHase, further regulating the second hydroxylation reaction of 25(OH)D into its 
hormonally active form.³⁶ ³⁹ ⁴⁰  
 
There are three primary single nucleotide polymorphisms for the Gc gene that codes 
for DBP, resulting in six inheritable diplotypes, each with varied functionality 
regarding the binding affinity of DBP for 25(OH)D or its metabolites.⁴¹¯⁴⁶ Whilst 
the significance between the functional variations of these Gc polymorphisms are not 
yet known, it has been suggested that they may result in different circulating and 
intracellular levels of vitamin D between individuals.¹⁵ ⁴⁷ Therefore, if these 
variations prove functional, future determinations of vitamin D status would require 
the measurement of  the DBP genotype and circulating 25(OH) vitamin D3.¹⁵ 
However to date, studies have failed to establish a consistent association between a 
DBP genotype and risk of specific diseases.⁴⁸¯⁵⁰  
 
The Vitamin D Receptor (VDR) 
The biological effects of VD3 are regulated by the VDR, a nuclear receptor expressed 
in many cell types.³⁰ ⁵¹ ⁵² Upon entry into the cell or through intracellular 
conversion from 25(OH)D, the metabolites 1,25(OH)₂D or 1,25(OH)₂D₃ will bind to 
nuclear VDR forming a VDR-complex.³³ The VDR-complex promotes 
heterodimerization with the retinoid-X receptor (RXR), ultimately functioning as a 
ligand-activated transcription factor that will bind vitamin D response elements 
https://repository.uwc.ac.za/
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(VDRE) in the promoter regions of target genes.²⁷  The complex has been shown to 
both promote and suppress the transcription of several genes when combined with 
transcription factors and co-regulatory proteins.³³  
 
Similarly to DBP, allelic variations in the VDR gene have subtle effects in protein 
production and function.¹⁷ ⁵³¯⁵⁶ One such recognized variant, X-linked 
hypophosphatemia (XLP), also referred to as ‘vitamin D resistant rickets’, is a sex 
linked dominant familial disorder resulting in excess phosphate excretion and 
impaired bone mineralization. Patients are resistant to vitamin D supplementation 
and treatment includes oral phosphate, calcitriol and surgery if necessary.⁵⁵  It is 
believed that other VDR variants may act as predisposing factors in immune-
mediated disease development, ²⁴ ⁵⁷ ⁵⁸ however, at this time inconsistent results 
surrounding VDR polymorphisms, a functional phenotype, and various disease states 
have been reported.¹⁵ ⁵⁶ Furthermore, it is likely other genes and complex 
interactions between these genes contribute to the extremely complex vitamin D 
regulatory system which may also affect susceptibility to immune-mediated disease, 
and is being actively researched.¹³   
 
Determination of Vitamin D status: serum 25(OH)D 
In the human body, serum 25(OH)D (a summation of both VD3 and VD2) is the 
recommended index to determine whether a patient has adequate, depleted or 
intoxicative amounts of vitamin D.⁵⁹¯⁶⁵  Despite 1,25(OH)₂D being the biologically 
active form, it is not recommended as a measurement index for vitamin D status as it 
only has a half-life of 4-6 hours, with circulating levels about one thousandth 
(measured in the picomolar range) that of 25(OH)D.⁶⁶ In addition, during vitamin D 
deficiency, intestinal calcium absorption is reduced, which transiently lowers ionized 
calcium triggering calcium sensors in the parathyroid gland to increase PTH  
production and secretion.⁶⁷  The PTH in turn acts to increase renal re-absorption of 
calcium, increase skeletal calcium mobilization, and increase the production of 
1,25(OH)₂D in the kidneys,⁶⁰ ⁶³  ⁶⁴ resulting in ‘normal’ or elevated serum 
1,25(OH)₂D concentrations, thus making measurement of this metabolite useless to 
determine vitamin D status.⁶⁶  
 
Although there is no absolute consensus for what a normal range for 25(OH)D 
should be, vitamin D deficiency or hypovitaminosis D is generally defined as a serum 
25(OH)D below ≤20ng/mL (a range still sufficient to prevent secondary 
hypoparathyroidism),⁶⁸ ⁶⁹ with serum 21-29 ng/mL regarded as vitamin D 
‘insufficient’, and serum  ≥30-36ng/mL being vitamin D ‘sufficient’ (Table 2).²⁰ ⁶⁰ ⁶¹  
⁷⁰ Values have been based on studies showing that serum PTH begins to plateau at 
serum 25(OH)D concentrations  ≥30ng/mL, and intestinal calcium transport 
efficiency is maximized when serum 25(OH)D levels are above 32ng/mL.⁶⁸   ⁷¹¯⁷³ 
The upper limit for serum 25(OH)D is considered to be  >60ng/mL and has been 
associated with hypercalcemia, hypercalciuria and often hyperphosphatemia, while 
values >100-150ng/mL have been associated with toxicity (Table 2).⁶¹ ⁶²  ⁷⁴ 
https://repository.uwc.ac.za/
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Conversely, vitamin D deficiency diseases like rickets (children) and osteomalacia 
(adults) have no recommended ‘optimal’ serum level as relatively low vitamin D 
levels may eliminate disease risk.⁵ ¹³  
 
Toxicity 
Hypervitaminosis D or vitamin D toxicity with excess 25(OH)D levels most 
commonly manifest as hypercalcemia. However in the literature, hypercalcemia 
directly resulting from large quantities of orally consumed supplemental vitamin D, 
has only been recorded in cases with 25(OH)D levels ranging from 128-648 ng/mL, 
achieved after prolonged oral supplementation with dosages from upwards of 
10,000-40,000 IU/day.¹⁵ ⁷⁵ In general, serum 25(OH)D concentrations of >100-
150ng/mL will produce a vitamin D toxicity in the human body,  yet these values may 
be slightly lower for children.⁷⁶ There is no evidence of vitamin D toxicity after 
prolonged UV sun exposure as increases in pre-vitamin D3 concentrations lead to an 
increase in the formation of inactive vitamin D compounds, which acts as a natural 
protective mechanism.²⁸ ⁷⁵ Therefore concerns about skin cancer risk may be the 
only contraindication for direct and prolonged exposure to the sun.  
 
Immune regulation in Crohn’s disease 
Th1, Th2 and Th17 response 
Immune regulation is driven by the functional differentiation of naïve CD4+ T cells 
into Th1, Th2, Th17 and CD4+ T-regulatory (T-reg) cell phenotypes.⁷⁷ Each of these 
governing immune cell responses, and the critical balance between them, are 
mediated by key regulatory cytokines produced by both macrophages and DCs.¹³  ¹⁴ 
⁷⁷ In terms of the Th1 response, host defence against tumors or pathogens (viruses) 
results in a ‘normal’ up-regulation of the pro-inflammatory (Th1)  helper T-cells, 
which leads to the secretion of the pro-inflammatory cytokines; interferon gamma 
(abbreviated either IFN-y or INF-y), interleukin-2 (IL-2), and tumor necrosis factor 
alpha (TNF-α), and ultimately defence against the foreign pathogen.  Traditionally, 
IFN-y mediates the Th1 response, and IFN-y itself is directly induced by interleukin-
12 (IL-12), a cytokine produced by antigen-presenting cells (APCs). ⁷⁸ ⁷⁹  
 
During CD however, chronic gastrointestinal inflammation and mucosal damage is 
propagated by an exaggerated Th1 T-cell immune response to the commensal 
(‘normal’) bacteria residing in the gut. The T-cell production of Th1 cytokines (IL-2, 
IFN-y and TNF-α) fuels the immune-mediated attack against intestinal cells during 
IBD, and has been associated with IBD symptoms in humans,⁸⁰ and the transfer of 
Crohn’s like symptoms to naïve mice.⁸¹  ⁸² In particular,  pro-inflammatory cytokines 
TNF-α and IFN-y are thought to directly contribute to disease pathogenesis by 
damaging the epithelial mucosa and increasing its permeability to both bacterial and 
dietary antigens, the latter considered a hallmark characteristic of CD.³ ⁸³¯⁸⁷ 
 
Conversely, the function of the Th2 cells is to secrete interleukin-4 (IL-4) and 
interleukin-5 (IL-5), both essential components of antibody-mediated immunity.¹⁴ 
https://repository.uwc.ac.za/
7 
 
The Th2 cells are produced in response to extracellular pathogens such as bacteria 
and parasites. When the Th2 cells are abnormally up-regulated in response to 
environmental antigens, conditions such as asthma and allergies develop, 
alternatively, in CD disease, there is a down-regulation of the Th2 response.  
 
The fairly recent characterization of a third T-cell mechanism involved in IBD 
pathogenesis, distinct from the Th1 or Th2 cells of cellular immunity, comprises the 
Th17 immune response, a CD4+ T cell subset now believed to play an integral role in 
maintaining inflammation, which may lead to tissue damage.⁸⁸  The functional 
development Th17 cells is indirectly induced by the cytokine interleukin-23 (IL-23) 
and mediated by the cytokine interleukin-17 (IL-17).⁸⁹ ⁹⁰   While IL-12 (direct 
inducer of IFN-y in Th1 response) and IL-23 are heterodimers and both associated 
with the pathogenesis of CD, unlike IL-12 (a heterodimer of p40 and p35 subunit), 
IL-23 (heterodimer of same p40 subunit as IL-12 with a unique p19 subunit) cannot 
directly regulate naïve CD4+ T cells in adopting the Th17 phenotype.⁹¹ Instead, 
initial Th17 cells are generated by the collective activity of transforming growth 
factor-beta (TGFβ) and interleukin-6 (IL-6).⁹¹ Only after initial Th17 cell generation, 
do the cells gain the ability to express the IL-23 receptor allowing their terminal 
differentiation, and the persistence of cytokines IL-17, interleukin-22 (IL-22) and 
interleukin-21 (IL-21).⁹² ⁹³  It is important to note that after the  initial generation of 
Th17 cells via TGFβ and IL-6, in the absence of IL-23, Th17 cells lack the ability to 
induce inflammation, and instead produce the anti-inflammatory cytokine 
interleukin-10 (IL-10).⁹⁴  
 
The role of IL-23 and the Th17 immune response surrounding intestinal 
inflammation was initially demonstrated in immunodeficient (RAG-deficient or 
SCID mice) murine models with experimentally induced colitis, later reconstituted 
with naïve T-cells.⁹³  When the RAG-deficient mice were also made deficient in p35 
(thus unable to produce IL-12 and abbreviated as IL-23p35), colitis developed. The 
IL-23p35-deficient mice exhibited a marked increase in colonic IL-17 with moderate 
reductions in TNF-α and IFN-y. Conversely, when the mice were instead made to be 
p19 deficient (thus unable to produce IL-23 and abbreviated as IL-23p19), intestinal 
inflammation did not develop, and marked reductions in colonic TNF-α and IFN-y, 
with mild increases in colonic IL-17, were observed. Both models did however 
develop splenomegaly and hepatomegaly, suggesting that underlying systemic 
inflammation is driven by both IL-12 and IL-23.⁹⁵ The difference in colonic IL-17 
concentrations between the two models (IL-23p35-deficient mice with markedly 
increased colonic IL-17 versus IL-12p19-deficient with mildly increased colonic IL-
17) also implies that the IL-17 cytokine may be down-regulated by the Th1 response, 
and not entirely controlled by IL-23. ⁹³ ⁹⁶ The contributory role of CD4+ Th17 cells 
was further underscored after the transfer of bacterial reactive CD4+ Th17 cells 
resulted in a more severe form of colitis in immunodeficient murine models, when 
compared to those transferred with bacterial reactive CD4+ Th1 cells. As in most 
experimental colitis, elevated concentrations of both IL-23 (intestine) and IL-17 
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(serum and mucosa) have been identified in CD patients, ⁹⁷¯¹⁰⁰ and administration 
of anti-cytokine therapy (e.g., anti-IL-12p40) has proven beneficial.⁹⁸  
 
It is important to point out however, that after the transfer of T-cells to IL-23p19-
deficient/RAG1-deficient mice, colitis still developed due to the presence of an intact 
IFN-y response, provided there was an absence of regulatory T-cell development 
caused by either an IL-10 or TGFβ deficiency. Moreover, IL-23p19-deficient mice 
exhibited an increase in regulatory T-cell concentrations, and IL-23p19-
deficient/RAG1-deficient mice with an inability to develop regulatory T-cells (e.g., 
those lacking Foxp3), also developed colitis after the transfer of T-cells.⁹³  ¹⁰¹ Based 
on these findings, it is possible that the contributory effect of IL-23p19 may be 
through the down-regulation or ‘neutralization’ of T-regulatory responses such as 
Th1, rather than the failure of Th1 to moderate colitis, thus explaining why the 
immunodeficient (RAG-deficient or SCID mice) IL-23p19-deficient mice did not 
develop colitis.⁹³ Therefore, despite recent reports demonstrating the IL-12/IFN-y 
and IL-23/IL-17 pathways as mutually exclusive (i.e., IFN-y shown to suppress IL-17 
and vice versa),¹⁰² ¹⁰³ it is possible that the Th1 and Th17 responses co-exist during 
CD pathogenesis, each governing different phases of the dynamic inflammatory 
process that occurs in human CD (in comparison to that of CD mouse models), 
however the extent of their relationship is not yet fully explicated.⁹³ ¹⁰⁴  
 
Vitamin D and immune regulation 
Th1, Th2 and Th17 Response 
The bioactive form of vitamin D (1,25[OH]₂D)  is now known to directly target T-cell 
function. For instance, in Th1 cells, 1,25(OH)₂D has been shown to suppress purified 
T-cell proliferation, reduce IFN-y and IL-2 production, and increase the production 
of IL-5 and IL-10, ¹⁰⁵¯¹⁰⁸ while in the Th2 cells, there is an up-regulation of IL-4 
production,¹⁰⁵ ultimately resulting in an overall shift away from a Th1 phenotype 
towards a more tolerogenic Th2 phenotype.²³  ¹⁰⁹¯¹¹⁶ In addition, it was shown that 
the activation of CD4+ T cells ensued a five-fold increase in VDR expression allowing 
the regulation of 102 identified 1,25(OH)₂D-responsive genes.¹¹⁰ ¹¹¹ 
  
Supporting evidence was first demonstrated in VDR knockout (KO) murine models 
(i.e., vitamin D signalling inhibited), which exhibited an up-regulated pro-
inflammatory Th1 response (higher INF-y cytokine production), and down-regulated 
Th2 response (lower IL-4, IL-5 production) compared to wild-type (WT) mice.¹¹⁷ 
Interestingly, the uncorrected vitamin D deficiency in these VDR KO mice resulted in 
an accelerated form of experimental IBD, that subsequently improved after 
1,25(OH)₂D₃ administration, as Th1 pro-inflammatory cytokine production 
decreased, and Th2 cell secretion of IL-4 increased. ¹³  ¹⁰⁵ ¹¹⁸  ¹¹⁹ The 
administration of 1,25(OH)₂D₃ was then evaluated in transgenic IL-10 KO murine 
models, as IL-10 plays a regulatory role based on its ability to suppress Th1 cytokine 
synthesis. Interleukin-10 KO mice are known to spontaneously develop IBD, 
exhibiting severe enterocolitis within 5-8 weeks of life, with a resultant 30% 
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mortality.¹²⁰ The uncontrolled immune response is directed towards commensal 
intestinal flora, as germ-free IL-10 KO mice did not develop the disease.¹⁴ Upon the 
administration of 1,25(OH)₂D₃ however, the IL-10 KO mice exhibited reduced 
inflammation, mortality and an improvement in IBD symptoms. While the KO mice 
models may not be representative of a “normal” immune reaction, the symptoms 
exhibited in the mice models are similar to symptoms in CD patients who present 
with decreased serum IL-10,¹²¹ and in human cells, the administration of 
1,25(OH)₂D₃ and dexamethasone increased the production and function of T-reg 
CD4+ T cells, via IL-10 stimulation¹²² and the T-reg-associated cytokine TGFβ1.¹²³   
Notable suppression of IBD has also been demonstrated via dietary manipulation of 
vitamin D when combined with calcium, in IL-10 KO mice.¹²⁴ ¹²⁵  Murine IL-10 KO 
models were divided into four groups, each receiving one of four diets namely; a diet 
deficient in 1,25(OH)₂D₃  with no added calcium (0.2%), a diet deficient in 
1,25(OH)₂D₃ with high concentrations of calcium (2.2%), a diet treated with 
20ng/day 1,25(OH)₂D₃ with no added calcium, or a diet treated with 20ng/day 
1,25(OH)₂D₃ with high calcium. Serum calcium levels and intestinal weights were 
later measured. It was found that the group receiving the high 1,25(OH)₂D₃ and high 
calcium diet maintained a similar intestinal composition compared to that of the WT 
control mice, while the 1,25(OH)₂D₃ and calcium deficient groups developed 
symptomatic IBD. 
 
Recently however, two independent studies reported that the administration of 
1,25(OH)₂D₃ in naïve murine precursers failed to inhibit¹²⁶/resulted in negligible 
effects¹¹³ on Th1 cell differentiation, and intriguingly, compared to Th17 cells, VDR 
mRNA in the Th1 cells was found to be approximately 30-fold lower. ¹¹³ Although 
the role of vitamin D and the T-cell phenotype Th17 has not yet been fully elucidated, 
in vitro studies have demonstrated a partial suppression of Th17 cell developmental 
programming, with increased IL-10 expression after 1,25(OH)₂D₃ administration, 
¹¹³ and in naïve CD4+ T cells, the metabolite inhibited IL-6 expression, an 
important cofactor for Th17 cell differentiation.¹²⁷ ¹²⁸  Moreover, murine models 
with experimentally induced intestinal inflammation exhibited a reduction of IL-17 
expression after 1,25(OH)₂D₃ administration,¹²⁹ whilst the absence of 1,25(OH)₂D₃ 
(secondary to CYP27B1 gene ablation) resulted in elevated IL-17 concentrations.¹³⁰   
 
Anti-microbial peptides 
The innate immune system is the first barrier of defence against foreign organisms. 
The cellular response of the innate immune system involves a cascade of events 
largely triggered by two classes of pathogen recognition receptors, namely pathogen-
associated molecular patterns or PAMPs (e.g., lipopolysaccharide, flagellin, viral 
proteins and single-and double stranded RNA) and toll-like receptors (TLRs), the 
latter being a sub-class of recognition receptor expressed on cell membranes or 
endosomes.¹³¹ In humans, TLR signalling results in the production of anti-microbial 
peptides namely; cathelicidin and the α- and β-defensins.¹³² Cathelicidin is 
produced when cells lining epithelial surfaces (e.g., skin, respiratory tract, 
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gastrointestinal tract),¹³³¯¹³⁵ neutrophils or macrophages are exposed to potential 
pathogens. Cathelicidin plays an integral role in innate immune function, and when 
deficient, whether in humans or cathelicidin KO mice, ‘barrier site’ (i.e., mucosal 
membranes and epithelial surfaces) infections are more prone to develop.²⁸ The 
effect of vitamin D on anti-microbial peptides was first demonstrated in cell lines and 
primary cultures (including ones derived from skin, macrophages, neutrophils, lung 
and colon) treated with 1,25(OH)₂D₃, as it lead to the up-regulation of cathelicidin 
mRNA. Furthermore, it has been reported that the promotor region of genes coding 
for both cathelicidin and β-defensin possess the VDRE.¹³⁶¯¹³⁸ In human 
macrophages, TLR stimulation lead to an up-regulation of the VDR and cellular 1α-
OHase production (CYP27B1) allowing cellular conversion of 25(OH)D into 
1,25(OH)₂D, and in the presence of TLR stimulation, cathelicidin mRNA in human 
macrophages is up-regulated by 1,25(OH)₂D₃.²⁸ ¹³⁹ Conversely, in vitro, when the 
VDR or CYP27B1 are inhibited, or when 25(OH)D substrate levels are low, 
cathelicidin is no longer up-regulated,¹⁴⁰ implying that the underlying pathway in 
terms of local 1,25(OH)₂D production (i.e., VDR and cellular 1α-OHase up-
regulation) which enhances cathelicidin production, can only occur when vitamin D 
status is adequate.²⁸ ¹³⁹   
 
Dendritic cells and the Epithelial Barrier 
Dendritic cells are APCs which play a central role in antigen presentation to T-cells 
and have been associated with both the initiation and propagation of T-cell mediated 
gastrointestinal immune responses in IBD. Immature DCs function to promote T-cell 
tolerance whereas the function of mature DCs, is to activate naïve T-cells.¹⁴¹ ¹⁴² DCs 
express the VDR,¹⁴³ ¹⁴⁴ and their differentiation from monocytes,¹⁴⁵ maturation 
and survival are influenced by the availability of 1,25(OH)₂D, which when present, 
results in an overall more tolerogenic DC phenotype.²⁸ ⁵¹ ⁵⁷  ¹⁴⁶¯¹⁴⁸  The 
immunosuppressive effect of 1,25(OH)₂D₃ on DCs was shown in vivo ⁵⁷  ⁵⁸  ¹⁴⁶¯¹⁴⁸ 
to reduce Th1 development (inhibiting IL-12 production),¹³⁰ increase Th2 
development (promoting IL-10 production), ¹⁴⁶¯¹⁴⁸ and compared to T-cells 
cultured with control DCs, T-cells cultured with 1,25(OH)₂D₃-treated DCs secrete 
less pro-inflammatory cytokine IFN-y.¹⁴⁶  Likewise, administration of 1,25(OH)₂D₃ 
to DCs suppressed the expression of p40 (IL-12 cytokine),¹⁴⁹ which may in turn 
reduce the faction between Th1 and Th17 cells.¹⁵⁰  
 
The epithelial lining of the gastrointestinal tract from the stomach to the anus acts as 
a physical barrier to pathogens and as an immune regulator through antigen 
presentation.¹⁵¹ ¹⁵² Two types of intracellular junctions connect the epithelial cells 
and are referred to as either tight junctions or adherens junctions based on their 
functionality.¹⁵² ¹⁵³ These junctions are comprised of proteins called pore forming 
transmembranes. Defects in these proteins may lead to alterations in mucosal 
permeability to microbes thus increasing the risk for inflammation.¹⁵⁴ Claudin-2 is 
one pore forming transmembrane that has been implicated in the pathogenesis of 
IBD and its expression is ultimately induced by INF-y and inhibited by protein 
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tyrosine phosphatase N2 (abbreviated either PTPN2 or PTNP2).¹⁵ ¹⁵⁵  Interestingly, 
the gene bound to the VDR is in fact PTNP2 and the PTPN2 locus is considered as a 
high risk IBD locus associated with colonic CD and UC.¹⁵⁶ Consequently, the 
1,25(OH)₂D-VDR complex may act to impede the expression of PTNP2 thus 
inhibiting epithelial barrier pore formation and the altered intestinal permeability 
associated with disease development.¹⁵ ¹⁷    
 
Summary 
The immunoregulatory effect of vitamin D is an absolute result of the presence of 
VDR in cells involved in the human immune structure. The presence of 1,25(OH)₂D 
or 1,25(OH)₂D₃ may both directly and indirectly regulate T-cell immune function, 
albeit more research is needed to better elucidate the broad relationship between the 
Th1 and Th17 responses, including the contributory roles of vitamin D, respectively. 
Nevertheless, vitamin D metabolites have shown to increase the number and 
function of regulatory T-cells and regulate antigen presentation in DCs, each well-
established for their role in CD pathogenesis. For that reason, it appears that the 
ability for an immune system to properly develop and function optimally may be lost 
when vitamin D is deficient, potentially favouring the development of self-reactive T 
cells, and immune-mediated disease development. 
 
Vitamin D and Crohn’s disease  
Epidemiological evidence 
Crohn’s disease is one of 80 known immune-mediated disorders, affecting an 
estimated 1.4 million individuals in the United States and 2.2 million in Europe.² ¹⁵⁷ 
Disease activity usually follows a relapsing-remitting pattern, which may or may not 
be accompanied by a variety of extraintestinal manifestations (EIM).¹  ² When 
present, EIMs can occur in any organ however the joints (e.g., arthritis; most 
frequently observed EIM occurring in about 25% of cases), skin, biliary tract and eyes 
are most commonly involved.¹⁵⁸¯¹⁶¹ Disease activity is typically classified using 
either the Crohn’s disease activity index (CDAI)¹⁶² or the Harvey Bradshaw index 
(HBI).¹⁶³  
 
Similar to other immune-mediated inflammatory diseases, the actual development of 
disease reflects a complex interplay between genetics and an environmental 
trigger(s), and in the case of CD, the consequent abnormal gastrointestinal immune 
reaction to the intestinal microbiome.¹⁶⁴¯¹⁶⁶ Numerous gene mutations associated 
with; abnormal innate immune responses (NOD2/CARD15, TLR4, CARD9), 
differentiation of Th17 lymphocytes (IL-23R, JAK2, STAT3, CCR6, ICOSLG), 
autophagy (ATG16L1, IRGM, LRRK2), maintenance of epithelial barrier function 
(IBD5, DLG5, PTGER4, ITLN1, DMBT1, XBP1) and the initiation of secondary 
immune response (HLA-region, TNFSF15/TL1A, IRF5, PTPN2, PTPN22, NKX2-3, 
IL-12B, IL-18RAP, MST1), have been implicated in disease pathophysiology and 
susceptibility.¹⁶⁷¯¹⁷² Disease incidence is known to cluster within families, as 
approximately 5-20% of patients with CD have a family history of IBD, making it a 
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known risk factor.¹⁷³ ¹⁷⁴ Epidemiological studies show that in 75-80% of families 
with members suffering with IBD, affected members have similar disease type, with 
all members affected with either CD or UC.¹⁷³  In the remaining 20% of families, 
members are affected with ‘mixed’ forms, some with CD and some with UC, 
suggesting that CD and UC are to some extent genetically linked, sharing common 
IBD associated susceptibility genes.¹⁷³ ¹⁷⁴ However genetic predisposition alone 
cannot account for disease onset. While the cooperation between genetic and 
environmental factors in CD development is observed throughout epidemiologic and 
genetic based research, it is first best described via twin studies. In monozygotic 
(MZ) twins (genetically identical individuals), concordance rate for CD disease 
reaches only 20-50%, significantly higher compared to dizygotic twins (DZ) (0-7%).  
Yet, the lack of a 100% concordance rate in MZ twins implies a low genetic 
penetrance, thus rendering one or more environmental factors(s) instrumental in the 
disease aetiology.¹⁷⁵¯¹⁷⁸ Cigarette smoking is a well-established risk factor for CD 
development.¹⁷⁹¯¹⁸¹ Additional risk factors including appendectomy,¹⁸² oral 
contraceptive use,¹⁸³  breastfeeding,¹⁸⁴ antibiotic use¹⁸⁵ and to some extent dietary 
habits have also been recognized in the literature, albeit with inconsistent 
findings.¹⁸⁶ ¹⁸⁷ The role of environmental factors is further underlined by 
population studies, as families moving from low CD prevalence areas to high CD 
prevalence areas, subsequently developed an increased CD risk mirroring that to the 
overall population of that region, an effect particularly noted in first-generation 
children.¹⁸⁸¯¹⁹¹  
 
An association between vitamin D status (as an environmental constituent) and CD 
incidence was initially hypothesized based on epidemiological evidence, yet like any 
retrospective observational evidence, unable to imply a causal association.  For 
example, the long reported a ‘north-south’ gradient which shows a higher incidence 
and prevalence of CD in populations residing in northern Europe, North America, 
Australia and New Zealand compared to those in southern locales such as southern 
Europe, South America and Asia.¹⁹²¯¹⁹⁶ Theoretically the gradient may be explained 
because synthesis of VD3 primarily depends upon UV skin exposure; northern 
regions located at higher latitudes (i.e., North Europe, North America), with 
predictably lower yearly UV exposure, experience higher IBD rates, compared to 
southern regions that are closer to the equator experiencing greater yearly UV 
exposure, and thus the lower CD rates.¹⁵ ¹⁹⁶ Reinforcing evidence to support this 
link was further observed from a cohort analysis of the Nurses Health Study I and II, 
evaluating 72 719 women, where, compared to those residing in northern latitudes, 
women who resided in southern latitudes had a significantly lower risk of CD 
(Hazard ratio (HR) 0.48, 95% CI 0.03-0.77).¹⁹⁷  Similarly, Nerich et al¹⁹⁸ 
demonstrated a significant correlation between higher CD incidence rates and 
regions of lower sunlight exposure in France, ascertained using satellite data 
modelling surface UV radiation intensity, and a population wide health insurance 
database.  Migration studies have also shown that immigrants who move from 
regions located closer to the equator, to regions of more northern latitudes, develop 
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an increased risk for IBD,¹⁹⁹ and in general, the frequency of diagnosis and disease 
relapse rates reportedly peak during winter months.²⁰⁰¯²⁰²  Recently, 
Ananthakrishnan et al²⁰³ examined the association between predicted plasma 
25(OH)D (determined by dietary and lifestyle variables) and CD risk, in a female 
cohort from the National Health Survey.  Mean predicted 25(OH)D plasma levels 
were divided into quartiles ranging from 22ng/mL (lowest quartile) and 32 ng/mL 
(highest quartile), and evaluated using multivariate analysis. In keeping with the 
literature, the authors reported that women in the highest quartile had significantly 
half the incidence of CD (HR 0.54, 95% CI 0.30-0.99) compared to those in the 
lowest quartile.  
 
Intriguingly, a recent hypothesis was proposed suggesting that the widely observed 
increase in CD incidence over the last two decades may too be correlated with the 
global trend towards decreased outdoor activity, obesity, increased pollution 
(industrialization) and low dietary vitamin D intake, resulting in suboptimal vitamin 
D serum concentrations and the rising CD incidence.²⁷  ²⁰⁴ Moreover, vitamin D 
deficiency is often reported in newly diagnosed CD patients further alluding to its 
contributory role in disease development, although larger prospective studies are 
needed to imply causality.¹⁸ ²⁰⁰ ²⁰⁵ 
 
Deficiency in Crohn’s disease  
Vitamin D deficiency is common in CD patients throughout the disease course, with 
proportions ranging between 22% and 70%.⁷  ¹⁰ ¹⁸ ²⁰⁶¯²¹³ Inter-individual 
determinants of vitamin D status are influenced by ‘modifiable’ and/or ‘non-
modifiable’ factors. Modifiable determinants which may result in suboptimal vitamin 
D in the CD patient include; malnutrition (reduced dietary intake), malabsorption 
secondary to surgical resection or diseased mucosa (predominantly in the ileum),²¹⁴ 
protein losing enteropathy, reduced physical activity, prolonged corticosteroid 
use,²¹⁵ anti-convulsant therapy,²¹⁶ smoking,²¹⁷ and reduced sunlight exposure 
(seasonal variation)²⁰⁸ due to illness (Table 3).¹⁶ ²⁰⁹ ²¹³  ²¹⁸¯²²⁰  
       
Although somewhat counterintuitive, malnutrition in a CD patient can co-exist with 
overweight or obesity (Body mass index (BMI) >30), a scenario which is becoming 
increasingly prevalent in many CD patients.²²¹ Obesity has been associated with a 
higher risk of relapsing disease in the CD patient, and adipose tissue itself is now 
recognized for its pro-inflammatory actions and resultant low grade inflammatory 
state within the body.²²² ²²³ Interestingly, the increased adipose tissue present in 
overweight/obesity has also been associated with lower serum 25(OH)D, likely due to 
the increasing 25(OH)D storage pool with increasing adipose tissue.²²⁴ ²²⁵ Thus 
overweight and obesity in the CD patient may contribute a compounding effect to 
any pre-existing vitamin D deficiency or those at risk for deficiency.  
  
Non-modifiable determinants of vitamin D status include increasing age (lower 
cutaneous VD3 production),²²⁶ ²²⁷ darker skin pigmentation,⁵¹ longer disease 
https://repository.uwc.ac.za/
14 
 
duration or polymorphisms in the Gc (DBP protein), CYP24A1 (24 hydroxylase), 
DHCR7 (7-dehydrocholesterol reductase), and CYP2R1 (25 hydroxylase) genes, 
although the latter polymorphisms are currently considered to be less influential 
compared to the environmentally-based, ‘modifiable’ determinants.¹⁵ ²²⁸ ²²⁹ 
 
Serum response to oral vitamin D supplementation is known to vary between 
individuals, likely due to the variable interactions between different combinations of 
the aforementioned determinants.²⁰ Likewise, due to the progressive nature of most 
of these determinants in CD, serum response to oral supplementation within one 
individual may be variable over time.  Therefore regular monitoring of serum 
25(OH)D is prudent, particularly during high dose oral or intramuscular 
supplementation, or when trying to reverse suboptimal serum levels.²⁰  ²²⁰ ²³⁰¯²³²  
 
Bone health 
Osteoporosis occurs in up to half of CD patients²³³ and long term vitamin D 
deficiency in adult CD patients is associated with lower BMD and skeletal integrity. 
⁷¯¹⁰ ²³⁴¯²⁴⁰ The majority of reports however have been cross-sectional and 
observational in nature, and future prospective interventional studies controlling for 
the individual VDR and DBP genetic polymorphisms are needed to further delineate 
the relationship between these variants, and their individual and/or combined effects 
on vitamin D metabolism.  Nevertheless, an extensive series of reports have 
demonstrated significant improvements in BMD after vitamin D (dosages ranging 
between 400 to 1000IU/day of cholecalciferol) and calcium supplementation in CD 
patients, and overall it is well accepted that the preservation of skeletal integrity in 
CD remains a key function of vitamin D.²⁴¹¯²⁴⁴  
 
Serum Vitamin D and disease activity 
Low vitamin D status was first associated with disease activity in Cardiff, Wales 
during the summer months (May-July), based on a small cohort of 40 CD patients in 
1985 (Table 4).²⁴⁵ Plasma 25(OH)D₃ concentrations were significantly lower 
(mean± SD) in patients with active disease  (10.12±1.4 ng/mL, n=11), compared to 
those with inactive disease (15.72±7.32 ng/mL, n=29). However many of the patients 
with normal concentrations of 1,25(OH)₂D₃ also had raised PTH concentrations, and 
since vitamin D2 was not measured, the validity of the data may be questionable. 
Since then, various patient cohorts have been examined via cross-sectional, 
retrospective studies. For instance, in 2004 a Japanese study performed by Tajika et 
al²⁰⁷ during the winter months (December 2001-January 2002), found that lower 
25(OH)D levels were significantly related to longer disease duration (>15 years; 
r=0.46, P=0.003) and increased disease activity (r=0.44, P=0.005), determined 
using the CDAI in 33 CD outpatients (Table 4). Of the 33 patients, 9 (27.3%) were 
considered to be vitamin D deficient (<10ng/mL), and compared to 15 age and sex 
matched controls, no significant difference was found between 25(OH)D 
concentrations or incidence of vitamin D deficiency. Smoking status was not 
recorded and normal serum 25(OH)D was broadly defined as 10-55ng/mL. Later, 
https://repository.uwc.ac.za/
15 
 
Joseph et al²⁴⁶ examined 34 consecutive CD patients, and 34 age and sex matched 
controls diagnosed with irritable bowel syndrome (IBS) between August 2004 and 
April 2007 from the gastrointestinal department of Christian Medical College 
Hospital in Vellore, India (Table 4). The authors reported that disease severity 
(determined using the HBI) was negatively correlated with serum 25(OH)D levels 
(correlation coefficient -0.327; P=0.007) while sunlight exposure was found to be 
positively correlated with 25(OH)D levels (correlation coefficient 0.484; P<0.004), 
and 25(OH)D concentrations were significantly lower in CD patients compared to 
controls (CD patients versus controls; 16.25±10.8 versus 22.78±11.9 ng/ml; P<0.05). 
Serum 25(OH)D cut off values were defined as deficiency <20ng/mL, 20-32ng/mL 
as insufficient and sufficiency as ˃32ng/mL. Among the CD patients 27 (79%) were 
vitamin D deficient, 4 (12%) were insufficient and 3 (9%) were vitamin D sufficient, 
smoking status was not recorded. In Denmark, another cross-sectional study by 
Jorgensen et al²⁴⁷ conducted between June 2005- June 2006, of 182 CD patients 
and 62 controls, reported an inverse association between serum 25(OH)D, C-reactive 
protein (CRP) (P<0.05) and disease activity (determined using the CDAI, P<0.001), 
the latter maintaining significance following stratification by smoking habits, and 
insertion of smoking into a linear regression model (Table 4). The authors 
conservatively defined deficiency as <20ng/mL, with >20ng/mL being vitamin D 
replete, and a normal CRP being <74nmol/L. Crohn’s disease patients receiving 
vitamin D supplementation (400-800 IU/day) had significantly lower CDAI 
(P<0.05) and CRP (P=0.07) concentrations, compared to non-users, and those 
receiving oral vitamin D supplementation, during the ‘low-level’ sunlight exposure 
season (November through April) had also significantly higher 25(OH)D levels 
(30.8ng/mL) compared to non-users (17.6 ng/mL) (P<0.001), a difference which 
failed to maintain significance in the ‘high-level’ season (May through October) 
between supplement users (32 ng/mL) and non-users (34.4 ng/mL). No difference in 
serum 25(OH)D levels was found between cases and controls, whether they were 
taking vitamin D supplementation or not.  Similarly in a large retrospective 
observational study of 504 IBD (403 CD, 101 UC) patients followed from the Medical 
College of Wisconsins’ Inflammatory Bowel Disease center since 1999, Ulitsky et al¹⁸ 
found vitamin D deficiency to be independently associated with an increased disease 
activity (HBI≥3; OR 1.77, P=0.005) on multivariate analysis adjusting for current 
and past smoking and medication use, including 5-aminosalicylic acid compounds, 
immunomodulators and biologic agents (Table 4). A significant association between 
vitamin D deficiency, quality of life (assessed using a 10 point previously validated 
questionnaire²⁴⁸) and disease activity was also reported [regression coefficient 1.07 
(95% CI: 0.43, 1.71)]. Of the CD patients, 205 (51%) of whom were identified as being 
vitamin D deficient, defined as a serum 25(OH)D  <20ng/mL, with 20-30ng/mL as 
relatively insufficient and sufficiency as ≥31ng/mL. Interestingly, although the study 
was based in Wisconsin, a ‘higher latitude’ region, located in the north-central 
United States at 43ºN, the authors noted a paradoxical seasonal variation, as vitamin 
D deficiency was significantly more prevalent in the summer months compared to 
the winter months.   
https://repository.uwc.ac.za/
16 
 
 
While these previous reports appear to support the immunologic effect of vitamin D, 
they are not without limitations. First, the prevalence of vitamin D sufficiency or 
insufficiency (or the associated risk factors) described in these reports¹⁸ ²⁰⁷  ²⁴⁵¯²⁴⁷ 
are limited in their ability to prospectively examine the consequences of vitamin D 
deficiency due to the cross-sectional design. Second, the cumulative disease 
presentation was determined retrospectively, thus it is possible that vitamin D 
insufficiently (at the time of measurement) may have temporarily followed the 
outcome measured.²⁴⁹ Limitations such as these may explain recent contradictory 
findings reported from a small cross-sectional study by Hassan et al¹⁹ of sixty IBD 
patients (34 UC, 26 CD), conducted in Iran (36.20º latitude and 59.35º longitude), a 
four-season country with the maximum amount of sunshine in the summer (Table 
4). Serum 25(OH)D concentrations were reportedly lower in patients with inactive 
disease (defined as a CDAI ≥150) compared to those with active disease (11.5±7.2 
ng/mL versus 14.33±13.5 ng/mL), albeit the results failed to reach significance, even 
when UC and CD were considered separately. Interestingly, despite the geographical 
location of the study, 60 (95%) of the patients were found to be vitamin D deficient, 
when defined as ≤10 ng/mL, insufficiency as11-29 ng/mL and sufficiency as 
≥30ng/mL. As such, the strongest evidence to date supporting the 
immunomodulatory role of vitamin D comes from a recent large North American 
(Boston, Massachusetts) cohort of IBD patients evaluating 2 tertiary medical centers 
(Table 4).²⁴⁹ An extensive review of the electronic medical records of 3217 IBD 
patients (1763 CD patients) with ≥1 plasma 25(OH)D concentration measurements 
(modelled according to the lowest recorded measurement before the event of 
interest; surgery or hospitalization) was performed. Plasma measurements were 
stratified as; ‘normal’ (>30ng/mL), insufficient (20-29.9ng/mL) and deficient 
(<20ng/mL).  An association was found between plasma 25(OH)D (<20ng/mL) the 
increased risk for surgery (OR, 1.76; 95% CI, 1.24,2.51) and disease related 
hospitalization (OR, 2.07; 95% CI, 1.59, 2.68) when compared to those with a 
25(OH)D ≥30ng/mL after adjusting for age, gender, Charlson comorbidity index,²⁵⁰ 
season, medication (immunomodulator and anti-TNF therapy) and follow-up 
duration. A dose-response effect with CD-related hospitalizations was also observed 
as 25(OH)D concentrations progressively decreased. However, the most convincing 
findings from this study were realized when the authors restricted the cohort to 
patients having a minimum of 2 plasma 25(OH)D measures (median interval of 294 
days between each interval) previously recorded. Crohn’s disease patients who 
achieved a ‘normalization’ of plasma 25(OH)D concentrations after a prior vitamin D 
insufficiency (i.e., from <29.9ng/mL to ≥30ng/mL), demonstrated a subsequent 
reduced risk for surgery on multivariate analysis (OR, 0.56; 95% CI, 0.32,0.98), and 
significantly lower median CRP concentrations (10.7mg/dL versus 16.2 mg/dL, 
adjusted regression coefficient [β], -5.2; 95% CI, -9.5, -1.02), compared to those who 
remained deficient, suggesting that vitamin D is a biologically relevant parameter. 
The effect on hospitalizations did not maintain significance on multivariate analysis.  
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Still, the intra-study comparison of vitamin D determination methods is one caveat 
that should always be considered. For instance, it is self-evident that differences in 
serum vitamin D cut off values defining ‘sufficiency’ and ‘insufficiency’ will influence 
data interpretation, as well as differences in disease activity measurement tools 
(CDAI versus HBI) and exclusion criteria variations, as seen between the previous 
reports (Table 4).  Furthermore, variances in accuracy and precision between the 
measurement tools used to measure serum 25(OH)D concentration may influence 
findings. For example, the use of chemiluminescent assays or radioimmunoassays, 
which are more prone to interpretational and observational errors, have been the 
most readily available over the past two decades and therefore predominantly quoted 
in past literature.⁷⁵ ²⁵¹  ²⁵² Currently however, the most accurate assays are believed 
to be liquid chromatography mass spectrometry (LC-MS) as used by Jorgensen et 
al,²⁴⁷ and high performance liquid chromatography (HPLC), both becoming 
increasingly available.⁷⁵  A new ‘gold standard’ recently implemented in over 700 
laboratories worldwide now includes the use of a Vitamin D External Quality 
Assurance Scheme (DEQAS), which involves a quarterly ‘all laboratory trimmed 
mean’ evaluation to monitor and standardize the performance of 25(OH)D assays.⁷⁵  
²⁵³  
 
Regardless, it appears even when these variables are fairly consistent, disparaties 
between the reports regarding the proportion of vitamin D-deficient patients is 
evident, ¹⁸ ¹⁹ ²⁰⁷  ²⁴⁵¯²⁴⁷ a phenomenon likely attributable to region specific 
environmental or cultural determinants.²⁵⁴ For instance, the UV availability in a 
certain region may not necessarily equate to an individuals’ actual UV exposure, 
despite residing in that region. In countries with very hot climates spanning over the 
majority of the year, sun seeking may be an uncommon practice, especially in 
populations where beauty is associated with a fairer skin tone.²⁵⁴¯²⁵⁶ Clothing 
practices will also influence actual UV exposure on the skin, as seen in South Asia 
where clothing and wide brim hats usually cover most of the exposed skin, greatly 
minimizing or preventing sunlight exposure entirely.²⁵⁴  In particular, religious 
orientated clothing practices particularly that of the veil (hijab or niqab), have been 
independently associated with vitamin D deficiency in both African and Middle 
Eastern populations.²⁵⁷¯²⁶⁰ Moreover, ethnic or regional variations in food 
consumption practices regarding high intakes of fatty fish, cod liver oil, or dietary 
dairy products, as well as variations in government food fortification policies may 
also influence the vitamin D status between populations.²⁵⁹ A darker skin 
pigmentation will reduce cutaneous VD3 production compared to that of lighter skin 
individuals,²⁶¹ ²⁶² then again, the use of high protection sunscreen is becoming 
increasingly more common in lighter skin individuals, which may reduce or block 
entirely UV irradiation of the skin.²⁶³ Similarly, urbanization has been associated 
with lower vitamin D levels as individuals are more likely to work indoors²⁵⁹ ²⁶⁴  ²⁶⁵  
possibly in areas with higher air pollution, blocking, therefore reducing UV light 
exposure, compared to inhabitants of rural areas.²⁶⁶ Overall, future research in the 
form of large prospective studies and randomized trials taking into consideration the 
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aforementioned variables are required to definitively establish the role of vitamin D 
modulation in the CD patient.   
 
Vitamin D supplementation in Crohn’s disease  
Administration and formulation  
Clinical trials with vitamin D supplementation in CD patients have demonstrated an 
immunomodulatory effect, however methodological variations regarding the dosage 
administered, formulation of vitamin D provided, and duration of supplementation 
remain.  In a clinical trial by Jorgensen et al,²⁶⁷ the authors reported a reduction in 
relapse rates of 94 CD patients in remission (defined as CDAI<150) of 13% versus 
29% after 12 months, when administered 1200 IU/day cholecalciferol, however 
results failed to reach significance.  Yet over a shorter 26 week longer period, a 
trial²⁶⁸ of 15 CD patients reported that patients supplemented with larger doses of 
oral vitamin D provided as 10,000 IU/day cholecalciferol, had a significantly higher 
improvement of clinical scores compared to patients supplemented with only 
1,000IU/day cholecalciferol, suggesting that dosing thresholds may need to be 
established to optimize effectiveness. In comparison, a recent pilot study of 18 CD 
patients with mild-to-moderate CD (defined as CDAI 150-400) evaluated the CDAI 
scores, quality of life scores and the oral vitamin D dosage required to achieve a 
serum concentration above 40ng/mL.²⁶⁹ A daily dose of 1000IU was initiated and 
increased every two weeks by 1000IU until the goal serum of 40ng/mL, or until a 
maximum of 5000IU/day of cholecalciferol, was achieved. After 24 weeks, 
supplementation with up to the maximal dosage effectively raised serum 25(OH)D in 
patients. A significant improvement in both quality of life scores (P=0.0004) and a 
reduction in CDAI scores (P<0.0001) were reported in the patients. These findings 
suggest that restoration of normal serum vitamin D levels may be of most benefit in 
the management of CD patients with mild-to-moderate disease, regardless of the 
dosing prescription required to achieve this.  
 
There is insufficient evidence demonstrating whether oral ergocalciferol (VD2) 
compared to oral cholecalciferol (VD3) supplementation provides more clinical 
value,²⁷⁰¯²⁷² however it appears that cholecalciferol is preferred by many 
practitioners,³² and is also more widely available compared to ergocalciferol.¹⁵ ³² It 
must be noted however that in a short six week non-blinded trial of 37 CD patients in 
clinical remission (defined as CDAI<150),  patients (n=18) who were supplemented 
daily with a bioactive form of vitamin D, 1,25(OH)₂D (provided as 0.5ug/day 
alfacalidol, a vitamin D analogue), experienced improved CDAI scores and CRP 
values compared to the remaining patients (n=17) receiving “plain” vitamin D3 
(provided as 2000IU/day cholecalciferol).¹⁵ ²⁷³ Thus, it is possible that oral 
supplementation with a bioactive oral analogue of vitamin D may be superior to 
choelcalciferol. Since the dosage of cholecalciferol provided in the trial was relatively 
small, larger prospective trials are needed.²⁶⁸  
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Nevertheless, dosing practices with oral cholecalciferol, administering smaller, daily 
dosages compared to larger intermittent dosages, remains inconclusive. In a trial of 
26 vitamin D deficient patients,²⁷⁴ no difference in serum 25(OH)D target levels 
were found between patients administered 50,000IU/day cholecalciferol  for 10 days 
(500,000IU total dose), or those administered 3000IU/day cholecalciferol for one 
month followed by 1000IU/day for the following two months (total dose 150,000IU). 
Yet on a practical level, short term, intermittent high dose supplementation to 
reverse deficiency may be beneficial in the outpatient setting, in terms of 
convenience thus improved patient compliance, since shorter duration, large dose 
oral administration of vitamin D in deficient CD patients is deemed safe (Table 5).²⁰  
 
Supplementation 
Current United States Department of Agriculture (USDA)²⁷⁵ and the Institute of 
Medicine (IOM)²⁷⁶ guidelines recommend a daily dietary allowance of 600IU, with 
an upper level of 4000IU starting from the age of 9 though >70 years, which includes 
pregnant and lactating females.²⁷⁷  In the case of a low 25(OH)D, supplementation 
of 1500-2000IU/day may be required to achieve a serum of ≥30ng/mL.²⁰  These 
values need to be increased by a factor of 2-3 in obese individuals or those taking 
anti-convulsant therapy medication, the latter known for its disruptive effects on 
vitamin D metabolism.²⁰ ²⁷⁸ 
   
Conversely, in the CD patient, evidence indicates that there may be upwards of a 30% 
attenuated or diminished response to oral vitamin D supplementation compared to 
healthy individuals,²²⁰ and patients may require higher daily vitamin D intakes. In 
the case of suboptimal serum 25(OH)D concentrations of ≤3ng/mL, 4-≤9g/mL, 10-
≤15ng/mL, 16-≤23ng/mL and  24-≤29ng/mL CD patients should be started on daily 
oral cholecalciferol of 5000IU, 4000IU, 3000IU, 2000IU and 1000IU, respectively 
(Table 5).¹⁵ The dosage should be multiplied by a factor of 1.5-3 if small bowel 
involvement, malabsorption syndrome, or a BMI>30 is present,¹⁵  ²⁰ Large dose oral 
administration of vitamin D in vitamin D-deficient CD patients, following a regime of 
50,000IU of cholecalciferol once a week for eight weeks, or until target serum 
25(OH)D level is achieved, is deemed safe in the literature (Table 5).²⁰ In severe 
deficiency or where annual large vitamin D dosing may be appropriate, 
intramuscular doses of between 300,000-600,000IU of cholecalciferol have also 
shown to be safe and effective, however urinary calcium levels should be 
monitored.²⁷⁰¯²⁷² It is important to note, that the above oral vitamin D 
supplementation guidelines are intended as a starting reference considering the high 
variability of serum 25(OH)D in response to vitamin D supplementation between 
individuals.²⁷⁸ Therefore, baseline serum 25(OH)D levels should be re-checked at 
three months, then again every three to six months, adjusting the dosage until the 
target serum of 30-36ng/mL is achieved.¹⁵   Thereafter a maintenance dosage of 
1500-2000IU/day may be provided, however the upper threshold necessary for 
optimal outcome and maintenance, while avoiding any adverse consequences, has 
not yet been established (Table 5).¹⁵  
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Conclusion 
Vitamin D supplementation in the CD patient is known to have an advantageous 
effect regarding the maintenance of skeletal integrity. Recent evidence now suggests 
that vitamin D also functions as an immunoregulator via its actions on the VDR, and 
in the CD patient, adequate vitamin D status may reduce both disease activity and 
inflammation. Serum 25(OH)D is the recommended index to measure vitamin D 
status, however the upper threshold necessary for optimal outcome, while avoiding 
any adverse consequences, has not yet been fully established. Nevertheless, current 
consensus suggests that a serum 25(OH)D of  30-36ng/mL is sufficient to maintain 
serum PTH and maximize intestinal calcium transport, and when necessary, oral 
supplementation can be provided as either ergocalciferol (VD2) or cholecalciferol 
(VD3), however the latter is more commonly used. Oral cholecalciferol can be 
administered either in smaller daily dosages, or in larger intermittent dosages which 
may improve patient compliance. Regular monitoring of serum 25(OH)D is 
recommended as individual serum response to vitamin D supplementation may vary. 
Considering the epidemiological and molecular evidence together, it seems that 
vitamin D is intrinsic to the development and function of the human immune system, 
however future research surrounding the vitamin should be actively pursued. 
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Figure 1. The synthesis, metabolism and cellular effects of vitamin D. Dietary and sunlight 
derived vitamin D are converted into the biologically active form 1,25(OH)₂D by either immune 
cells or sequential hydroxylations in the liver and kidney, respectively. Inside the cell the VDR 
complex functions as a ligand-activated transcription factor that will bind vitamin D response 
elements in the promoter region of target genes subsequently promoting or suppressing gene 
expression. 
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Table 1.  Vitamin D: cholecalciferol (VD3) and ergocalciferol (VD2) 
 
Natural and Food sources: Vitamin D3  (cholecalciferol) 
UVB exposure from sunshine, full body exposure † ~10,000-20,000IU 
Cod liver oil (1tsp) ~400-1,000IU 
Salmon (fresh, wild, 100g) ~600-1,000IU  
Salmon (farmed, 100g) ~100-250 IU  
Fortified milk (250ml) 100IU  
Fortified orange juice (250ml) 100IU  
Egg yolk ‡  ~20IU/yolk 
Food Sources; Vitamin D2  (ergocalciferol) 
Shiitake mushrooms (fresh, 100g) ~100IU  
Shiitake mushrooms (sun dried, 100g) ~1600IU  
IU, International Units.    1 IU=25ng (nanograms). 
† A dark skinned individual may need 5-16 times more exposure to achieve the same 
amount of vitamin D compared to a fair skinned individual. 
‡ Contains both Vitamin D3 and Vitamin D2. 
 
 
 
Table 2. Interpretation of serum 25(OH)D concentration²⁰ ⁶²¯⁶⁴  ⁷⁰ ⁷⁴   
Serum 25(OH)D 
(ng/mL)ᵃ 
Interpretation of serum 25(OH) vitamin 
D  
concentration 
≤10 Severe deficiency 
≤20 Deficiency 
21-29 Insufficiency 
≥30-36 Sufficiency 
≥60 Upper limit; associated with hypercalcemia, 
hypercalciuria and hyperphosphatemia 
 >100-150 Toxicity 
ᵃ Conversion factor for ng/mL  to nmol/L is 2.496. 
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Table 3. Contributing factors for vitamin D deficiency in the Crohn’s disease patient 
¹⁵ ¹⁶ ⁵¹ ²⁰⁸ ²⁰⁹ ²¹³¯²¹⁸  ²²⁰ ²²⁴¯²²⁹  
 Malnutrition (reduced dietary intake) 
 Malabsorption  
 Protein losing enteropathy 
 Surgical resection (predominantly ileum) 
 Reduced physical activity 
 Lower bioavailability 
 Reduced sunlight exposure  
 Smoking 
 Prolonged corticosteroid therapy 
 Anti-convulsant therapy 
 Longer disease duration 
 Increasing age 
 Darker skin pigmentation (higher melanin content) 
 BMI ≥30 
 Genetic polymorphisms affecting vitamin D metabolism 
BMI, body mass index. 
 
 
 
Table 4: Vitamin D and disease activity in the adult Crohn’s disease patient 
Pre
vio
us 
stu
die
s 
IBD 
Sam
ple 
selec
tion 
Study 
locatio
n and 
season
al 
variati
on 
Serum 
25(OH) 
vitamin 
D 
measure
ment  
(ng/mL) 
Diseas
e 
activit
y 
evalua
tion 
tool 
(CDAI, 
CRP,H
BI) 
 
Participa
nt 
exclusion 
criteria 
Overall findingsᵃ 
Ha
rri
s 
198
5 
²⁴⁵ 
40 
CD  
patie
nts 
Cardiff, 
Wales  
 
Summer 
months: 
May-
July 
Plasma 
vitamin D3 
(25[OH]D₃
) 
measuredᵇ 
 
Radioimm
unoassay 
(sheep 
antiserum) 
HBI   Receiving 
oral vitamin 
D or 
cholestyra
mine 
supplement
ation 
25(OH)D₃ 
concentration 
significantly lower in 
patients with active 
disease (defined as 
HBI >5). 
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Taj
ika 
20
04 
²⁰⁷  
33 
CD 
patie
nts 
15 
age-
sex 
matc
hed 
contr
ols 
Japan 
 
Winter 
months: 
Decemb
er 2001-
January 
2002 
Serum 
25(OH)D  
 
Competitiv
e protein 
binding 
assay  
 
Cut off 
values: 
10-
55ng/mL 
sufficient 
CDAI  
 
Receiving 
vitamin D, 
calcium, 
calcitonin, 
bisphospho
nate, 
hormone 
replacemen
t or fluoride 
 
Diagnosed 
with 
kidney, 
liver, 
cardiopulm
onary, 
hypogonadi
sm and 
inflammato
ry joint 
disease 
 
Lower 25(OH)D 
concentration 
significantly correlated 
with longer disease 
duration and increased 
disease activity.  
 
No significant 
difference in 25(OH)D 
deficiency between 
cases and controls. 
Jos
ep
h 
20
09 
²⁴⁶ 
34 
CD 
patie
nts 
  
34 
age 
and 
sex 
matc
hed 
out-
patie
nt 
contr
ols 
with 
IBS 
India 
 
Consecu
tive 
patients 
recruite
d during 
April 
2004-
August 
2007 
Serum 
25(OH)D  
 
Radioimm
unoassay  
 
Cut off 
values: 
<20ng/mL 
deficiency,  
20-
32ng/mL 
insufficien
cy, 
>32ng/ml 
sufficient 
 
HBI, 
CRP 
Receiving 
supplement
al vitamin 
D or 
calcium 
over the 
past 6 
months 
 
Diagnosed 
with renal, 
hepatic, 
thyroid 
disease and 
pregnant 
women  
 
Significant negative 
correlation between 
disease severity, and 
significant positive 
correlation between 
duration of sunlight 
exposure with 
25(OH)D 
concentration.  
 
25(OH)D significantly 
lower in cases 
compared to controls. 
Jor
gen
sen 
182 
CD  
patie
Denmar
k 
 
Serum 
25(OH)D  
 
CDAI, 
CRP 
No 
exclusion 
criteria 
Low 25(OH)D 
significantly associated 
with active disease, 
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201
3 
²⁴⁷  
nts 
 
63 
healt
hy 
contr
ols 
Cross-
sectional 
study 
between  
June 
2005-
June 
2006 
 
Isotope 
diluted 
chromatog
raphy-
tandem 
mass 
spectromet
ry.  
 
 
Cut off 
values:  
<20ng/mL 
vitamin D 
deficiency, 
>20ng/mL 
vitamin D 
replete 
 
after adjusting for 
smoking habits.  
 
Oral vitamin D 
supplementation 
significantly improved 
serum 25(OH)D 
during months with 
‘low-level’ sunlight 
exposure.  
 
No significant 
difference in 25(OH)D 
between cases and 
controls. 
Table 4: Vitamin D and disease activity in the adult Crohn’s disease patient (cont.) 
 
Uli
tisk
y 
201
1¹⁸  
 
504 
IBD 
patie
nts  
 
(403 
CD,  
101 
UC)  
Wisonsi
n, USA 
 
Retrospe
ctive 
observat
ional; 
patients 
followed 
since 
1999 at 
Medical 
College 
of 
Wiscons
in IBD 
center  
Serum 
25(OH)D  
 
Chemilumi
nescent 
immunoas
say 
 
 
Cut off 
values: 
 
<20ng/mL 
deficiency,  
20-
30ng/mL 
relative 
insufficien
cy, 
>31ng/mL 
sufficiency 
 
HBI 
and a 
validate
d 
quality 
of life 
questio
nnaire²
⁴⁸  
No 
exclusion 
criteria 
 
 
Current and 
past 
smoking 
and 
medication 
use, 
including 5-
aminosalicy
lic acid 
compounds
, 
immunomo
dulators 
and biologic 
agents were 
recorded 
25(OH)D deficiency 
independently 
associated with 
increased CD disease 
activity (defined as 
HBI≥3) on 
multivariate analysis 
adjusting for current 
and past smoking and 
medication use, 
including 5-
aminosalicylic acid 
compounds, 
immunomodulators 
and biologic agents.  
 
Paradoxical seasonal 
variation, as deficiency 
significantly more 
prevalent in summer 
compared to winter 
months. 
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Ha
ssa
n 
201
3¹⁹  
 
60 
IBD 
patie
nts  
 
(26 
CD, 
34 
UC) 
Iran 
 
Summer 
months 
 
Serum 
25(OH)D  
 
Radioimm
unoassay.  
 
Cut off 
values: 
 <10ng/mL 
deficiency,  
11-
29ng/mL 
insufficien
cy,  
≥30ng/mL 
sufficient 
CDAI Receiving 
anticonvuls
ants, 
vitamin D 
supplement
ation 
 
Diagnosed 
with renal 
failure, liver 
disease, 
malabsorpti
on (defined 
as albumin 
<2mg/dl, 
cholesterol 
<100mg/dl,  
BMI 
≤18.5kg/m²
), and 
pregnancy 
or lactation 
 
No significant 
association between 
25(OH)D deficiency 
and IBD activity, even 
when CD and UC 
considered separately.  
An
ant
ha
k-
ris
hn
an 
201
3 
²⁴⁹  
3217 
IBD 
patie
nts 
 
(1763 
CD, 
1454 
UC) 
Boston, 
Massach
usetts 
USA 
 
Electron
ic 
medical 
record 
review 
of 2 
tertiary 
medical 
centers 
Plasma 
25(OH)D 
 
Liquid 
chromatog
raphy with 
mass 
spectromet
ry since 
2008, and 
radioimmu
noassay 
prior 2008 
 
Cut off 
values: 
 
<20ng/mL 
deficient, 
20-
29.9ng/mL 
Examin
ed IBD-
related 
surgery 
or 
hospital
ization 
No 
exclusion 
criteria 
25(OH)D (<20ng/mL) 
associated with 
increased risk for  
surgery and 
inflammatory bowel 
disease related 
hospitalization 
compared to patients 
with 25(OH)D 
(>30ng/mL). 
Normalization of 
25(OH)D (from 
<29.9ng/mL to 
≥30ng/mL) resulted in 
a reduced risk for 
subsequent IBD 
related surgery and 
lower median CRP 
levels.  
 
Results based on 
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insufficient
, 
>30ng/mL 
normal 
multivariate analysis 
adjusting for age, 
gender, Charlson 
comorbidity index,²⁵⁰ 
season, medication 
(immunomodulator 
and anti-TNF therapy) 
and follow-up 
duration. 
CD, Crohn’s disease, CDAI, Crohn’s disease activity index; CRP, C-reactive protein; 
HBI, Harvey-Bradshaw index; IBD, Inflammatory bowel disease; consists of two 
subtypes, Crohn’s disease (CD) and Ulcerative colitis (UC); IBS, Irritable bowel 
syndrome; ng/mL, nanogram per mililiter; UC, ulcerative colitis. 
ᵃ Overall findings for each study presented for Crohn’s disease (CD) patients. 
ᵇ Three plasma vitamin D3 assays were measured: 25(OH)D₃, 24,25(OH)₂D₃ and 
1,25(OH)₂D₃. No cut off values were defined in the study. Serum vitamin D2 
(25[OH]D₂) was not measured. 
 
 
 
 
Table 5.  Oral vitamin D supplementation guidelines in the Crohn’s disease 
patient¹⁵  ²⁰ 
Serum 25(OH)D ᵃ 
 
(ng/mL) 
Supplementation in the Crohn’s disease patient ᵇ ᶜ 
Oral cholecalciferol (vitamin D3) 
≤3 5000 IU/day 
4- ≤9 4000 IU/day 
10- ≤15 3000IU/day 
16- ≤23 2000 IU/day 
24- ≤29 1000 IU/day 
30- 36 1500-2000IU/day maintenance ᵃ 
ᵃ Regular monitoring of serum levels should be performed at 3 months, then 3-6 
monthly and adjust dosage until serum concentration of 30-36ng/mL is achieved. 
ᵇ Multiply the dosage by a factor of 1.5-3 in patients with body mass index >30, 
patients on medications that affect vitamin D metabolism or those with small bowel 
involvement and/or other malabsorption syndromes.¹⁵ 
ᶜ Administration of 50,000IU oral cholecalciferol once a week for eight weeks, or 
until target serum 25(OH)D level is achieved may be provided for improved patient 
compliance.²⁰ 
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